Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 15Carcinoma, Transitional Cell 15Urologic Neoplasms 4Ureteral Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Urethral Neoplasms 2Metastatic Urothelial Cancer 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urothelial Cancer 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Peripheral Nervous System Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Neoplasm Metastasis 1Muscle-invasive Bladder Cancer 1Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1Male Urogenital Diseases 1Head and Neck Neoplasms 1Female Urogenital Diseases 1Esophageal Neoplasms 1Carcinoma in Situ 1Advanced Solid Tumor 1

Interventions

Mitomycin 15Gemcitabine 13dodecyl maltoside 5BCG Vaccine 5erdafitinib 4apaziquone 4ALT-803 4Epirubicin 3viscum album peptide 2durvalumab 2VB4-845 2Imiquimod 2Docetaxel 25-aminolevulinic acid hexyl ester 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1pirarubicin 1pembrolizumab 1linrodostat 1hydroxycamptothecinum 1enfortumab vedotin 1catumaxomab 1Water 1Therapeutics 1Therapeutic Uses 1Standard of Care 1Polysorbates 1Photochemotherapy 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Non-Muscle Invasive Bladder Neoplasms × enfortumab vedotin × Clear all
NCT05014139 2025-11-20

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Astellas Pharma Inc

Phase 1 Terminated
37 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡